NO20020639L - Anvendelse av anti-CD20-antistoff ved behandling av non-Hodgkins-lymfom med involvering av benmarg - Google Patents

Anvendelse av anti-CD20-antistoff ved behandling av non-Hodgkins-lymfom med involvering av benmarg

Info

Publication number
NO20020639L
NO20020639L NO20020639A NO20020639A NO20020639L NO 20020639 L NO20020639 L NO 20020639L NO 20020639 A NO20020639 A NO 20020639A NO 20020639 A NO20020639 A NO 20020639A NO 20020639 L NO20020639 L NO 20020639L
Authority
NO
Norway
Prior art keywords
antibody
treatment
bone marrow
hodgkins lymphoma
involving bone
Prior art date
Application number
NO20020639A
Other languages
English (en)
Other versions
NO20020639D0 (no
Inventor
William Rastetter
Original Assignee
Biogen Idec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc filed Critical Biogen Idec Inc
Publication of NO20020639D0 publication Critical patent/NO20020639D0/no
Publication of NO20020639L publication Critical patent/NO20020639L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
NO20020639A 1999-08-11 2002-02-08 Anvendelse av anti-CD20-antistoff ved behandling av non-Hodgkins-lymfom med involvering av benmarg NO20020639L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14828799P 1999-08-11 1999-08-11
PCT/US2000/040459 WO2001010462A1 (en) 1999-08-11 2000-07-25 Treatment of patients having non-hodgkins lymphoma with bone marrow involvement with anti-cd20 antibodies

Publications (2)

Publication Number Publication Date
NO20020639D0 NO20020639D0 (no) 2002-02-08
NO20020639L true NO20020639L (no) 2002-04-11

Family

ID=22525101

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20020639A NO20020639L (no) 1999-08-11 2002-02-08 Anvendelse av anti-CD20-antistoff ved behandling av non-Hodgkins-lymfom med involvering av benmarg

Country Status (11)

Country Link
EP (1) EP1207906A4 (no)
JP (1) JP2003513012A (no)
CN (2) CN100389825C (no)
AU (1) AU784971B2 (no)
CA (1) CA2378646A1 (no)
HK (1) HK1048945A1 (no)
MX (1) MXPA02001398A (no)
MY (1) MY136635A (no)
NO (1) NO20020639L (no)
TW (1) TWI279233B (no)
WO (1) WO2001010462A1 (no)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2904259C (en) 1999-05-07 2016-11-15 Genentech, Inc. Use of rituximab to treat vasculitis
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
NZ581541A (en) 2002-10-17 2011-07-29 Genmab As Human monoclonal antibodies against CD20
JP4351674B2 (ja) 2002-12-16 2009-10-28 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体とその使用法およびその使用
AU2004229376B2 (en) 2003-04-09 2007-12-13 Genentech, Inc. Therapy of autoimmune disease in a patient with an inadequate response to a TNF-alpha inhibitor
NZ543960A (en) 2003-05-09 2008-11-28 Univ Duke CD20-specific antibodies and methods of employing same
CA2526402A1 (en) 2003-06-05 2005-01-20 Genentech, Inc. Blys antagonists and uses thereof
RS57466B1 (sr) 2003-11-05 2018-09-28 Roche Glycart Ag Molekuli koji se vezuju za antigen sa povećanim afinitetom vezivanja za fc receptor i efektornom funkcijom
WO2005103081A2 (en) 2004-04-20 2005-11-03 Genmab A/S Human monoclonal antibodies against cd20
CN102512675A (zh) 2004-06-04 2012-06-27 健泰科生物技术公司 用于治疗多发性硬化的方法
US7740847B2 (en) 2004-08-04 2010-06-22 Applied Molecular Evolution, Inc. Variant Fc regions
AU2006272597A1 (en) 2005-07-25 2007-02-01 Emergent Product Development Seattle Llc Single dose use of CD20-specific binding molecules
ES2539250T3 (es) 2005-07-25 2015-06-29 Emergent Product Development Seattle, Llc Reducción de células B mediante el uso de moléculas de unión específica a CD37 y de unión específica a CD20
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
US9726673B2 (en) 2005-11-23 2017-08-08 Genentech, Inc. Methods and compositions related to B cell assays
CA2654317A1 (en) 2006-06-12 2007-12-21 Trubion Pharmaceuticals, Inc. Single-chain multivalent binding proteins with effector function
CA2691692C (en) 2007-07-09 2021-05-18 Genentech, Inc. Prevention of disulfide bond reduction during recombinant production of polypeptides
HUE030134T2 (en) 2007-10-16 2017-04-28 Zymogenetics Inc Combination of transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) and anti-CD20 agents for the treatment of autoimmune diseases
US7914785B2 (en) 2008-01-02 2011-03-29 Bergen Teknologieverforing As B-cell depleting agents, like anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
EP2077281A1 (en) 2008-01-02 2009-07-08 Bergen Teknologioverforing AS Anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
CN105198997B (zh) 2008-04-11 2018-08-31 阿普拜佛研发有限责任公司 Cd37免疫治疗剂及其与双功能化学治疗剂的联合
AR073295A1 (es) 2008-09-16 2010-10-28 Genentech Inc Metodos para tratar la esclerosis multiple progresiva. articulo de fabricacion.
BRPI0923579A2 (pt) 2008-12-22 2020-01-14 Millennium Pharm Inc combinação de inibidores de aurora quinase e anticorpos anti-cd20
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
JO3434B1 (ar) 2009-07-31 2019-10-20 Millennium Pharm Inc مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري
LT2464725T (lt) 2009-08-11 2020-06-10 F. Hoffmann-La Roche Ag Baltymų gamyba ląstelių mitybinėje terpėje, kurioje nėra glutamino
BR112012020102A2 (pt) 2010-02-10 2016-11-29 Immunogen Inc anticorpos cd20 e usos dos mesmos.
JP2013520424A (ja) 2010-02-19 2013-06-06 ミレニアム ファーマシューティカルズ， インコーポレイテッド ナトリウム４−｛［９−クロロ−７−（２−フルオロ−６−メトキシフェニル）−５Ｈ−ピリミド［５，４−ｄ］［２］ベンゾアゼピン−２−イル］アミノ｝−２−メトキシベンゾエートの結晶形
US9814740B2 (en) * 2010-12-21 2017-11-14 Duke University Methods and compositions combining immunotherapy with monocyte activation
US10017739B2 (en) 2012-09-06 2018-07-10 Duke University Methods of expanding and assessing B cells and using expanded B cells to treat disease
WO2014153509A1 (en) 2013-03-22 2014-09-25 Millennium Pharmaceuticals, Inc. Combination of catalytic mtorc 1/2 inhibitors and selective inhibitors of aurora a kinase
EP3247395A1 (en) * 2015-01-23 2017-11-29 Immunomedics, Inc. Combination therapy with anti-cd74 and anti-cd20 antibodies in patients with relapsed and refractory b-cell non-hodgkin's lymphoma
IL292708B1 (en) 2015-05-30 2024-04-01 Molecular Templates Inc Vaccine-free Shiga toxin A subunit scaffolds and cell-targeting molecules containing them
RS62986B1 (sr) 2015-06-24 2022-03-31 Hoffmann La Roche Antitela na transferinski receptor sa prilagođenim afinitetom
BR112018005573A2 (pt) 2015-09-21 2019-01-22 Aptevo Research And Development Llc ?polipeptídeos de ligação a cd3?
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
TWI819458B (zh) 2015-10-02 2023-10-21 瑞士商赫孚孟拉羅股份公司 雙特異性抗‐人類cd20/人類轉鐵蛋白受體抗體及使用方法
US20190192703A1 (en) * 2016-09-16 2019-06-27 Nordic Nanovector Asa Treatment of non-hodgkin lymphoma using lilotomab and 177lu-lilotomab satetraxetan
CN108421048B (zh) * 2016-09-28 2021-04-20 首都医科大学附属北京世纪坛医院 纳米活性碳靶向药物递送系统、制备方法及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RO118524B1 (ro) * 1992-11-13 2003-06-30 Idec Pharmaceuticals Corp San Metoda pentru tratarea unei tulburari legata de celulele b
US5595721A (en) * 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
DE69939939D1 (de) * 1998-08-11 2009-01-02 Idec Pharma Corp Kombinationstherapien gegen b-zell-lymphome beinhaltend die verabreichung von anti-cd20-antikörpern
US6451284B1 (en) * 1999-08-11 2002-09-17 Idec Pharmaceuticals Corporation Clinical parameters for determining hematologic toxicity prior to radioimmunotheraphy
US8557244B1 (en) * 1999-08-11 2013-10-15 Biogen Idec Inc. Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody

Also Published As

Publication number Publication date
MY136635A (en) 2008-11-28
NO20020639D0 (no) 2002-02-08
EP1207906A1 (en) 2002-05-29
CN100389825C (zh) 2008-05-28
AU784971B2 (en) 2006-08-10
MXPA02001398A (es) 2002-08-12
CN1373671A (zh) 2002-10-09
CN101259270A (zh) 2008-09-10
HK1048945A1 (en) 2003-04-25
AU7626000A (en) 2001-03-05
EP1207906A4 (en) 2005-07-06
CA2378646A1 (en) 2001-02-15
WO2001010462A1 (en) 2001-02-15
TWI279233B (en) 2007-04-21
JP2003513012A (ja) 2003-04-08

Similar Documents

Publication Publication Date Title
NO20020639L (no) Anvendelse av anti-CD20-antistoff ved behandling av non-Hodgkins-lymfom med involvering av benmarg
EE05073B1 (et) Retigabiin kasutamiseks neuropaatilise valu ravis
EE200100480A (et) Ksenoon kasutamiseks närvimürgistuste ravis
PL370029A1 (en) 2-amino-4-heteroarylaminopyrimidine derivatives for use in the treatment of cancer
EE05507B1 (et) Rosuvastatiini ZD4522) kasutamine heterosgootseperekondliku hperkolesteroleemia raviks
NO20016035D0 (no) Anvendelse av antistoff mot CD20 ved behandling av avstötning av implantanter
AU2002243495A1 (en) Bone morphogenetic protein-2 in the treatment and diagnosis of cancer
DE60045394D1 (de) Zusammensetzungen gegen infektionen zur behandlung erkrankten gewebes wie z.b. fieberbläschen
AU2001293553A1 (en) Phosphatidylserine-carrying apoptosis-mimicking bodies and the use thereof in medical treatment
HK1061212A1 (en) Pyranoindazoles and their use for the treatment ofglaucoma
EE200200571A (et) Hüdroksüfenüülpiperidiin-4-ülideenmetüülbensamiidi derivaadid valu raviks
AU2001283285A1 (en) Antimicrobial composition and methods of use in the treatment of disease
GB0019302D0 (en) Biological materials and the use thereof for the treatment of disease
HUP0303236A3 (en) Carbamate compounds for use in the treatment of pain
AU9279601A (en) Compounds and methods for use thereof in the treatment of cancer or viral infections
EE200200577A (et) Kinolinüülpiperidiin-4-ülideenmetüülbensamiidi derivaadid valu raviks
EE200200511A (et) Hüdroksüfenüülpiperasinüülmetüülbensamiidi derivaadid valu raviks
EE200200479A (et) Eksemestaani kasutamine rinnavähi ravis
DE10081194D2 (de) Darreichungsform zur Applikation in Körperöffnungen
AU2002340251A8 (en) Use of mx gtpases in the prognosis and treatment of cancer
ID30458A (id) Osanetan dalam pengobatan gangguan jiwa
AU5565401A (en) Materials and methods for the treatment of depression
AU2002366195A8 (en) Use of bisindolmaleimide and gemcitabine for the treatment of cancer
EE200200348A (et) Ravimkoostis kasutamiseks valu ravis
GB0106316D0 (en) Apparatus for use in the treatment of hair

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application